$11.160
+0.436 (+3.91%)Zum Schluss
TLX-News
TLX-Events
Telix Pharmaceuticals Stock Down 9.9% to $10.06
Telix Pharmaceuticals is down -9.9%, or -$1.10 to $10.06.
Telix Pharmaceuticals Stock Down 10.1% to $10.03
Telix Pharmaceuticals is down -10.1%, or -$1.13 to $10.03.
Telix Confirms FY26 Revenue Exceeds $1B
Telix reaffirmed that FY26 revenue and other income is expected to be in excess of $1B, with revenue tracking in line with upper end of FY26 guidance of $950M-$970M plus $40M of other income. The Company has also revised its FY26 R&D expenditure guidance range to $240M to $260M.
Genomic Medicine CEO Expects Over 25% Revenue Growth in 2026
Christian Behrenbruch, Managing Director and Group CEO, stated, "Demand for both Gozellix and Illuccix remained strong during the quarter, with U.S. dose volumes increasing 1% quarter-over-quarter, in line with our expectations and reflecting expected summer seasonality. We are pleased by the strong September exit run rate, supporting our confidence in delivering over 25% Precision Medicine revenue growth in 2026. We achieved an important milestone with the FDA approval of Pixclara, expanding our commercial portfolio, establishing a presence in neuro-oncology and further diversifying our revenue base. During the quarter, we announced a transformative merger with ITM, creating a leading vertically integrated radiopharmaceutical company with one of the industry's broadest therapeutic pipelines and expanded isotope production and global manufacturing capabilities. This is aligned with our long-term growth strategy reinforcing our ability to reliably serve patients at scale."
Telix Pharmaceuticals Collaborates with Ekalia to Advance US Production of Astatine-211
Telix Pharmaceuticals and Ekalia, a joint venture between Ion Beam Applications and Framatome, announced a collaboration to advance scalable United States production of astatine-211, an alpha-emitting radioisotope being investigated for targeted alpha therapy. The collaboration brings together IBA's specialized alpha-beam cyclotron technology, Framatome's nuclear and isotope production expertise, and Telix's U.S. radiopharmacy and "last-mile" infrastructure, clinical portfolio and radiopharmaceutical development capabilities. The alliance expands into the U.S. the strategic partnership formed by IBA and Framatome in Europe to advance industrial-scale At production. The first installation at RLS Trevose is intended to establish a reproducible production model, with the potential for further rollout across the RLS network as demand develops.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.